Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,220
archived clinical trials in
HIV / AIDS

An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated:  5/21/2013
State Univ of New York at Stony Brook
mi
from
Stony Brook, NY
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated: 5/21/2013
State Univ of New York at Stony Brook
mi
from
Stony Brook, NY
Click here to add this to my saved trials
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated:  5/21/2013
SUNY Upstate Medical University Hospital
mi
from
Syracuse, NY
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated: 5/21/2013
SUNY Upstate Medical University Hospital
mi
from
Syracuse, NY
Click here to add this to my saved trials
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated:  5/21/2013
New York Medical College
mi
from
Valhalla, NY
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated: 5/21/2013
New York Medical College
mi
from
Valhalla, NY
Click here to add this to my saved trials
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated:  5/21/2013
Metro Health Medical Center
mi
from
Cleveland, OH
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated: 5/21/2013
Metro Health Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated:  5/21/2013
Local Institution
mi
from
Youngstown, OH
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated: 5/21/2013
Local Institution
mi
from
Youngstown, OH
Click here to add this to my saved trials
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated:  5/21/2013
St. Jude Children's Research Hospital
mi
from
Memphis, TN
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated: 5/21/2013
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated:  5/21/2013
Local Institution
mi
from
Houston, TX
An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection
US Sustiva Oral Liquid Expanded Access Program: an Open-label, Multicenter Expanded Access Study of the Liquid Formulation of Sustiva (Efavirenz, DMP 266)
Status: Enrolling
Updated: 5/21/2013
Local Institution
mi
from
Houston, TX
Click here to add this to my saved trials
Quality of Life in Children With HIV Infection
Quality of Life in Children With HIV Infection
Status: Enrolling
Updated:  5/24/2013
University of Medicine and Dentistry of NJ
mi
from
Newark, NJ
Quality of Life in Children With HIV Infection
Quality of Life in Children With HIV Infection
Status: Enrolling
Updated: 5/24/2013
University of Medicine and Dentistry of NJ
mi
from
Newark, NJ
Click here to add this to my saved trials
Smoking Cessation Using Motivational Therapy and Varenicline
Smoking Cessation and the Natural History of HIV-Associated Emphysema
Status: Enrolling
Updated:  6/4/2013
Ohio State University
mi
from
Columbus, OH
Smoking Cessation Using Motivational Therapy and Varenicline
Smoking Cessation and the Natural History of HIV-Associated Emphysema
Status: Enrolling
Updated: 6/4/2013
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Violence and HIV Risk Among Women
HIV Risk Reduction for Women Reporting Intimate Partner Violence
Status: Enrolling
Updated:  6/10/2013
University of Rochester
mi
from
Rochester, NY
Violence and HIV Risk Among Women
HIV Risk Reduction for Women Reporting Intimate Partner Violence
Status: Enrolling
Updated: 6/10/2013
University of Rochester
mi
from
Rochester, NY
Click here to add this to my saved trials
Evaluating Rewards-Based Adherence and Electronic Medication Monitoring in HIV-Positive Adolescents
Incentives and Technology Survey 2013: Evaluation of Acceptance of Incentive-Based Adherence Programs and Electronic Medication Monitoring Among HIV-Positive Adolescents
Status: Enrolling
Updated:  6/13/2013
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Evaluating Rewards-Based Adherence and Electronic Medication Monitoring in HIV-Positive Adolescents
Incentives and Technology Survey 2013: Evaluation of Acceptance of Incentive-Based Adherence Programs and Electronic Medication Monitoring Among HIV-Positive Adolescents
Status: Enrolling
Updated: 6/13/2013
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Trial of Collaborative Depression Care Management for HIV Patients
Strategies to Link Antidepressant and Antiretroviral Management at Duke, UAB and UNC
Status: Enrolling
Updated:  6/26/2013
University of Alabama at Birmingham 1917 Clinic
mi
from
Birmingham, AL
Trial of Collaborative Depression Care Management for HIV Patients
Strategies to Link Antidepressant and Antiretroviral Management at Duke, UAB and UNC
Status: Enrolling
Updated: 6/26/2013
University of Alabama at Birmingham 1917 Clinic
mi
from
Birmingham, AL
Click here to add this to my saved trials
Trial of Collaborative Depression Care Management for HIV Patients
Strategies to Link Antidepressant and Antiretroviral Management at Duke, UAB and UNC
Status: Enrolling
Updated:  6/26/2013
University of North Carolina Hospitals Infectious Diseases Clinic
mi
from
Chapel Hill, NC
Trial of Collaborative Depression Care Management for HIV Patients
Strategies to Link Antidepressant and Antiretroviral Management at Duke, UAB and UNC
Status: Enrolling
Updated: 6/26/2013
University of North Carolina Hospitals Infectious Diseases Clinic
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Trial of Collaborative Depression Care Management for HIV Patients
Strategies to Link Antidepressant and Antiretroviral Management at Duke, UAB and UNC
Status: Enrolling
Updated:  6/26/2013
Duke University Clinic 2J
mi
from
Durham, NC
Trial of Collaborative Depression Care Management for HIV Patients
Strategies to Link Antidepressant and Antiretroviral Management at Duke, UAB and UNC
Status: Enrolling
Updated: 6/26/2013
Duke University Clinic 2J
mi
from
Durham, NC
Click here to add this to my saved trials
Pharmacokinetics, Pharmacodynamics and Cervicovaginal Lavage of Combined Oral Contraceptives and Raltegravir
Pharmacokinetics, Pharmacodynamics and Genital Tract Viral Shedding in HIV+ Women Using Combined Oral Contraceptives and Raltegravir
Status: Enrolling
Updated:  6/27/2013
UNC Infectious Disease Clinic
mi
from
Chapel Hill, NC
Pharmacokinetics, Pharmacodynamics and Cervicovaginal Lavage of Combined Oral Contraceptives and Raltegravir
Pharmacokinetics, Pharmacodynamics and Genital Tract Viral Shedding in HIV+ Women Using Combined Oral Contraceptives and Raltegravir
Status: Enrolling
Updated: 6/27/2013
UNC Infectious Disease Clinic
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Safety and Immune Response Assessment Study of Killed-whole HIV-1 Vaccine (SAV001-H) in Chronic HIV-1 Infected Patients
A Phase I, Randomized, Observer-blinded, Placebo-controlled Clinical Study to Assess the Safety, Tolerability, and Immune Response of Killed-Whole HIV-1 Vaccine (SAV001-H) Administered Intramuscularly to Chronic HIV-1 Infected Patients Currently Under Treatment With Highly Active Antiretroviral Therapy (HAART)
Status: Enrolling
Updated:  7/2/2013
Anthony Mills, MD Internal Medicine
mi
from
Los Angeles, CA
Safety and Immune Response Assessment Study of Killed-whole HIV-1 Vaccine (SAV001-H) in Chronic HIV-1 Infected Patients
A Phase I, Randomized, Observer-blinded, Placebo-controlled Clinical Study to Assess the Safety, Tolerability, and Immune Response of Killed-Whole HIV-1 Vaccine (SAV001-H) Administered Intramuscularly to Chronic HIV-1 Infected Patients Currently Under Treatment With Highly Active Antiretroviral Therapy (HAART)
Status: Enrolling
Updated: 7/2/2013
Anthony Mills, MD Internal Medicine
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Home Self-Testing for HIV to Increase HIV Testing Frequency in Men Who Have Sex With Men (The iTest Study)
Comparisons of Public Health Screening Methods for Acute and Early HIV Infection: Home Self-Testing for HIV Infection
Status: Enrolling
Updated:  7/11/2013
Public Health - Seattle & King County STD Clinic, located at Harborview Medical Center
mi
from
Seattle, WA
Home Self-Testing for HIV to Increase HIV Testing Frequency in Men Who Have Sex With Men (The iTest Study)
Comparisons of Public Health Screening Methods for Acute and Early HIV Infection: Home Self-Testing for HIV Infection
Status: Enrolling
Updated: 7/11/2013
Public Health - Seattle & King County STD Clinic, located at Harborview Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients
A Phase 1 Dose Escalation, Single Dose Study of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-278 in HIV-Infected Patients Who Have Exhibited Suboptimal CD4+ T-Cell Gains During Long-Term Antiretroviral Therapy
Status: Enrolling
Updated:  7/18/2013
UCLA Center for AIDS Research and Education
mi
from
Los Angeles, CA
Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients
A Phase 1 Dose Escalation, Single Dose Study of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-278 in HIV-Infected Patients Who Have Exhibited Suboptimal CD4+ T-Cell Gains During Long-Term Antiretroviral Therapy
Status: Enrolling
Updated: 7/18/2013
UCLA Center for AIDS Research and Education
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients
A Phase 1 Dose Escalation, Single Dose Study of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-278 in HIV-Infected Patients Who Have Exhibited Suboptimal CD4+ T-Cell Gains During Long-Term Antiretroviral Therapy
Status: Enrolling
Updated:  7/18/2013
Orange Coast Medical Group
mi
from
Newport Beach, CA
Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients
A Phase 1 Dose Escalation, Single Dose Study of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-278 in HIV-Infected Patients Who Have Exhibited Suboptimal CD4+ T-Cell Gains During Long-Term Antiretroviral Therapy
Status: Enrolling
Updated: 7/18/2013
Orange Coast Medical Group
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients
A Phase 1 Dose Escalation, Single Dose Study of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-278 in HIV-Infected Patients Who Have Exhibited Suboptimal CD4+ T-Cell Gains During Long-Term Antiretroviral Therapy
Status: Enrolling
Updated:  7/18/2013
Quest Clinical Research
mi
from
San Francisco, CA
Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients
A Phase 1 Dose Escalation, Single Dose Study of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-278 in HIV-Infected Patients Who Have Exhibited Suboptimal CD4+ T-Cell Gains During Long-Term Antiretroviral Therapy
Status: Enrolling
Updated: 7/18/2013
Quest Clinical Research
mi
from
San Francisco, CA
Click here to add this to my saved trials
Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients
A Phase 1 Dose Escalation, Single Dose Study of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-278 in HIV-Infected Patients Who Have Exhibited Suboptimal CD4+ T-Cell Gains During Long-Term Antiretroviral Therapy
Status: Enrolling
Updated:  7/18/2013
Circle CARE Center, LLC
mi
from
Norwalk, CT
Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients
A Phase 1 Dose Escalation, Single Dose Study of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-278 in HIV-Infected Patients Who Have Exhibited Suboptimal CD4+ T-Cell Gains During Long-Term Antiretroviral Therapy
Status: Enrolling
Updated: 7/18/2013
Circle CARE Center, LLC
mi
from
Norwalk, CT
Click here to add this to my saved trials
Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients
A Phase 1 Dose Escalation, Single Dose Study of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-278 in HIV-Infected Patients Who Have Exhibited Suboptimal CD4+ T-Cell Gains During Long-Term Antiretroviral Therapy
Status: Enrolling
Updated:  7/18/2013
Wohlfeiler, Piperato and Associates, LLC
mi
from
Miami Beach, FL
Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients
A Phase 1 Dose Escalation, Single Dose Study of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-278 in HIV-Infected Patients Who Have Exhibited Suboptimal CD4+ T-Cell Gains During Long-Term Antiretroviral Therapy
Status: Enrolling
Updated: 7/18/2013
Wohlfeiler, Piperato and Associates, LLC
mi
from
Miami Beach, FL
Click here to add this to my saved trials
Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients
A Phase 1 Dose Escalation, Single Dose Study of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-278 in HIV-Infected Patients Who Have Exhibited Suboptimal CD4+ T-Cell Gains During Long-Term Antiretroviral Therapy
Status: Enrolling
Updated:  7/18/2013
Orlando Immunology Center
mi
from
Orlando, FL
Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients
A Phase 1 Dose Escalation, Single Dose Study of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-278 in HIV-Infected Patients Who Have Exhibited Suboptimal CD4+ T-Cell Gains During Long-Term Antiretroviral Therapy
Status: Enrolling
Updated: 7/18/2013
Orlando Immunology Center
mi
from
Orlando, FL
Click here to add this to my saved trials
Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients
A Phase 1 Dose Escalation, Single Dose Study of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-278 in HIV-Infected Patients Who Have Exhibited Suboptimal CD4+ T-Cell Gains During Long-Term Antiretroviral Therapy
Status: Enrolling
Updated:  7/18/2013
Central West Clinical Research, Inc.
mi
from
St Louis, MO
Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients
A Phase 1 Dose Escalation, Single Dose Study of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-278 in HIV-Infected Patients Who Have Exhibited Suboptimal CD4+ T-Cell Gains During Long-Term Antiretroviral Therapy
Status: Enrolling
Updated: 7/18/2013
Central West Clinical Research, Inc.
mi
from
St Louis, MO
Click here to add this to my saved trials
Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients
A Phase 1 Dose Escalation, Single Dose Study of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-278 in HIV-Infected Patients Who Have Exhibited Suboptimal CD4+ T-Cell Gains During Long-Term Antiretroviral Therapy
Status: Enrolling
Updated:  7/18/2013
Southwest CARE Center
mi
from
Santa Fe, NM
Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients
A Phase 1 Dose Escalation, Single Dose Study of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-278 in HIV-Infected Patients Who Have Exhibited Suboptimal CD4+ T-Cell Gains During Long-Term Antiretroviral Therapy
Status: Enrolling
Updated: 7/18/2013
Southwest CARE Center
mi
from
Santa Fe, NM
Click here to add this to my saved trials
Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients
A Phase 1 Dose Escalation, Single Dose Study of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-278 in HIV-Infected Patients Who Have Exhibited Suboptimal CD4+ T-Cell Gains During Long-Term Antiretroviral Therapy
Status: Enrolling
Updated:  7/18/2013
Ricky K. Hsu, Md, Pc
mi
from
New York, NY
Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients
A Phase 1 Dose Escalation, Single Dose Study of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-278 in HIV-Infected Patients Who Have Exhibited Suboptimal CD4+ T-Cell Gains During Long-Term Antiretroviral Therapy
Status: Enrolling
Updated: 7/18/2013
Ricky K. Hsu, Md, Pc
mi
from
New York, NY
Click here to add this to my saved trials
Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients
A Phase 1 Dose Escalation, Single Dose Study of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-278 in HIV-Infected Patients Who Have Exhibited Suboptimal CD4+ T-Cell Gains During Long-Term Antiretroviral Therapy
Status: Enrolling
Updated:  7/18/2013
Gordon Crofoot MD, PA
mi
from
Houston, TX
Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients
A Phase 1 Dose Escalation, Single Dose Study of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-278 in HIV-Infected Patients Who Have Exhibited Suboptimal CD4+ T-Cell Gains During Long-Term Antiretroviral Therapy
Status: Enrolling
Updated: 7/18/2013
Gordon Crofoot MD, PA
mi
from
Houston, TX
Click here to add this to my saved trials
Raltegravir (Isentress/MK-0518) and HIV-1 Infected CD4 Cells During Acute/Early HIV-1
Impact of Raltegravir (Isentress/MK-0518) - Containing Regimens on HIV-1 Infected CD4+ T-Cells During Acute and Early HIV-1 Infection: A Randomized, Controlled Study Comparing Standard Antiretroviral Therapy to Standard Therapy Plus Raltegravir
Status: Enrolling
Updated:  8/8/2013
University of Washington Primary Infection Clinic
mi
from
Seattle, WA
Raltegravir (Isentress/MK-0518) and HIV-1 Infected CD4 Cells During Acute/Early HIV-1
Impact of Raltegravir (Isentress/MK-0518) - Containing Regimens on HIV-1 Infected CD4+ T-Cells During Acute and Early HIV-1 Infection: A Randomized, Controlled Study Comparing Standard Antiretroviral Therapy to Standard Therapy Plus Raltegravir
Status: Enrolling
Updated: 8/8/2013
University of Washington Primary Infection Clinic
mi
from
Seattle, WA
Click here to add this to my saved trials
Evaluation of a Blood Test to Measure Immune Function in HIV Positive People Compared With HIV Negative People
QuantiFERON® Monitor Test to Evaluate Immune Function in HIV Infected and Uninfected Control Study Subjects
Status: Enrolling
Updated:  8/12/2013
Sutter Street Internal Medicine
mi
from
San Francisco, CA
Evaluation of a Blood Test to Measure Immune Function in HIV Positive People Compared With HIV Negative People
QuantiFERON® Monitor Test to Evaluate Immune Function in HIV Infected and Uninfected Control Study Subjects
Status: Enrolling
Updated: 8/12/2013
Sutter Street Internal Medicine
mi
from
San Francisco, CA
Click here to add this to my saved trials
Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV
Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV
Status: Enrolling
Updated:  8/15/2013
NMCSD
mi
from
San Diego, CA
Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV
Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV
Status: Enrolling
Updated: 8/15/2013
NMCSD
mi
from
San Diego, CA
Click here to add this to my saved trials
Safety, Pharmacokinetics, Pharmacodynamics, and Disintegration Time of Vaginal Tablets Containing Tenofovir and/or Emtricitabine
A Phase I Clinical Trial Assessing the Safety, Pharmacokinetics, Pharmacodynamics, and Disintegration Time of Vaginal Tablets Containing Tenofovir and/or Emtricitabine
Status: Enrolling
Updated:  8/19/2013
Albert Einstein College of Medicine
mi
from
Bronx, NY
Safety, Pharmacokinetics, Pharmacodynamics, and Disintegration Time of Vaginal Tablets Containing Tenofovir and/or Emtricitabine
A Phase I Clinical Trial Assessing the Safety, Pharmacokinetics, Pharmacodynamics, and Disintegration Time of Vaginal Tablets Containing Tenofovir and/or Emtricitabine
Status: Enrolling
Updated: 8/19/2013
Albert Einstein College of Medicine
mi
from
Bronx, NY
Click here to add this to my saved trials
Safety, Pharmacokinetics, Pharmacodynamics, and Disintegration Time of Vaginal Tablets Containing Tenofovir and/or Emtricitabine
A Phase I Clinical Trial Assessing the Safety, Pharmacokinetics, Pharmacodynamics, and Disintegration Time of Vaginal Tablets Containing Tenofovir and/or Emtricitabine
Status: Enrolling
Updated:  8/19/2013
Clinical Research Center at Eastern Virginia Medical School
mi
from
Norfolk, VA
Safety, Pharmacokinetics, Pharmacodynamics, and Disintegration Time of Vaginal Tablets Containing Tenofovir and/or Emtricitabine
A Phase I Clinical Trial Assessing the Safety, Pharmacokinetics, Pharmacodynamics, and Disintegration Time of Vaginal Tablets Containing Tenofovir and/or Emtricitabine
Status: Enrolling
Updated: 8/19/2013
Clinical Research Center at Eastern Virginia Medical School
mi
from
Norfolk, VA
Click here to add this to my saved trials
Single Dose Escalation Study of GSK2838232 in Healthy Subjects
A Double-Blind, Randomized, Placebo-Controlled, Single Dose Escalation First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2838232 and to Evaluate the Effect of Food and Ritonavir on GSK2838232 in Healthy Subjects
Status: Enrolling
Updated:  9/5/2013
GSK Investigational Site
mi
from
Bethesda, MD
Single Dose Escalation Study of GSK2838232 in Healthy Subjects
A Double-Blind, Randomized, Placebo-Controlled, Single Dose Escalation First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2838232 and to Evaluate the Effect of Food and Ritonavir on GSK2838232 in Healthy Subjects
Status: Enrolling
Updated: 9/5/2013
GSK Investigational Site
mi
from
Bethesda, MD
Click here to add this to my saved trials
Tissue Drug Levels of HIV Medications
A Compartmental Analysis of HIV Reservoirs and Immune Reconstitution
Status: Enrolling
Updated:  9/13/2013
Univ of Minnesota
mi
from
Minneapolis, MN
Tissue Drug Levels of HIV Medications
A Compartmental Analysis of HIV Reservoirs and Immune Reconstitution
Status: Enrolling
Updated: 9/13/2013
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study
Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study
Status: Enrolling
Updated:  9/24/2013
San Francisco General Hospital
mi
from
San Francisco, CA
Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study
Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study
Status: Enrolling
Updated: 9/24/2013
San Francisco General Hospital
mi
from
San Francisco, CA
Click here to add this to my saved trials
Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)
Quality of Life of HIV-infected Patients Switched to Raltegravir Versus Other Antiretroviral Regimens
Status: Enrolling
Updated:  9/27/2013
Clinical Research Facility
mi
from
Hobson City, AL
Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)
Quality of Life of HIV-infected Patients Switched to Raltegravir Versus Other Antiretroviral Regimens
Status: Enrolling
Updated: 9/27/2013
Clinical Research Facility
mi
from
Hobson City, AL
Click here to add this to my saved trials
Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)
Quality of Life of HIV-infected Patients Switched to Raltegravir Versus Other Antiretroviral Regimens
Status: Enrolling
Updated:  9/27/2013
Clinical Research Facility
mi
from
Little Rock, AR
Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)
Quality of Life of HIV-infected Patients Switched to Raltegravir Versus Other Antiretroviral Regimens
Status: Enrolling
Updated: 9/27/2013
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)
Quality of Life of HIV-infected Patients Switched to Raltegravir Versus Other Antiretroviral Regimens
Status: Enrolling
Updated:  9/27/2013
Clinical Research Facility
mi
from
Berkeley, CA
Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)
Quality of Life of HIV-infected Patients Switched to Raltegravir Versus Other Antiretroviral Regimens
Status: Enrolling
Updated: 9/27/2013
Clinical Research Facility
mi
from
Berkeley, CA
Click here to add this to my saved trials
Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)
Quality of Life of HIV-infected Patients Switched to Raltegravir Versus Other Antiretroviral Regimens
Status: Enrolling
Updated:  9/27/2013
Clinical Research Facility
mi
from
Long Beach, CA
Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)
Quality of Life of HIV-infected Patients Switched to Raltegravir Versus Other Antiretroviral Regimens
Status: Enrolling
Updated: 9/27/2013
Clinical Research Facility
mi
from
Long Beach, CA
Click here to add this to my saved trials
Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)
Quality of Life of HIV-infected Patients Switched to Raltegravir Versus Other Antiretroviral Regimens
Status: Enrolling
Updated:  9/27/2013
Clinical Research Facility
mi
from
Irvine, CA
Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)
Quality of Life of HIV-infected Patients Switched to Raltegravir Versus Other Antiretroviral Regimens
Status: Enrolling
Updated: 9/27/2013
Clinical Research Facility
mi
from
Irvine, CA
Click here to add this to my saved trials
Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)
Quality of Life of HIV-infected Patients Switched to Raltegravir Versus Other Antiretroviral Regimens
Status: Enrolling
Updated:  9/27/2013
Clinical Research Facility
mi
from
Sacramento, CA
Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)
Quality of Life of HIV-infected Patients Switched to Raltegravir Versus Other Antiretroviral Regimens
Status: Enrolling
Updated: 9/27/2013
Clinical Research Facility
mi
from
Sacramento, CA
Click here to add this to my saved trials
Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)
Quality of Life of HIV-infected Patients Switched to Raltegravir Versus Other Antiretroviral Regimens
Status: Enrolling
Updated:  9/27/2013
Clinical Research Facility
mi
from
Sacramento, CA
Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)
Quality of Life of HIV-infected Patients Switched to Raltegravir Versus Other Antiretroviral Regimens
Status: Enrolling
Updated: 9/27/2013
Clinical Research Facility
mi
from
Sacramento, CA
Click here to add this to my saved trials
Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)
Quality of Life of HIV-infected Patients Switched to Raltegravir Versus Other Antiretroviral Regimens
Status: Enrolling
Updated:  9/27/2013
Clinical Research Facility
mi
from
Hartford, CT
Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)
Quality of Life of HIV-infected Patients Switched to Raltegravir Versus Other Antiretroviral Regimens
Status: Enrolling
Updated: 9/27/2013
Clinical Research Facility
mi
from
Hartford, CT
Click here to add this to my saved trials
Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)
Quality of Life of HIV-infected Patients Switched to Raltegravir Versus Other Antiretroviral Regimens
Status: Enrolling
Updated:  9/27/2013
Clinical Research Facility
mi
from
Washington,
Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)
Quality of Life of HIV-infected Patients Switched to Raltegravir Versus Other Antiretroviral Regimens
Status: Enrolling
Updated: 9/27/2013
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)
Quality of Life of HIV-infected Patients Switched to Raltegravir Versus Other Antiretroviral Regimens
Status: Enrolling
Updated:  9/27/2013
Clinical Research Facility
mi
from
Brandon, FL
Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)
Quality of Life of HIV-infected Patients Switched to Raltegravir Versus Other Antiretroviral Regimens
Status: Enrolling
Updated: 9/27/2013
Clinical Research Facility
mi
from
Brandon, FL
Click here to add this to my saved trials
Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)
Quality of Life of HIV-infected Patients Switched to Raltegravir Versus Other Antiretroviral Regimens
Status: Enrolling
Updated:  9/27/2013
Clinical Research Facility
mi
from
Gainesville, FL
Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)
Quality of Life of HIV-infected Patients Switched to Raltegravir Versus Other Antiretroviral Regimens
Status: Enrolling
Updated: 9/27/2013
Clinical Research Facility
mi
from
Gainesville, FL
Click here to add this to my saved trials
Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)
Quality of Life of HIV-infected Patients Switched to Raltegravir Versus Other Antiretroviral Regimens
Status: Enrolling
Updated:  9/27/2013
Clinical Research Facility
mi
from
Orange City, FL
Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)
Quality of Life of HIV-infected Patients Switched to Raltegravir Versus Other Antiretroviral Regimens
Status: Enrolling
Updated: 9/27/2013
Clinical Research Facility
mi
from
Orange City, FL
Click here to add this to my saved trials
Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)
Quality of Life of HIV-infected Patients Switched to Raltegravir Versus Other Antiretroviral Regimens
Status: Enrolling
Updated:  9/27/2013
Clinical Research Facility
mi
from
Fort Lauderdale, FL
Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)
Quality of Life of HIV-infected Patients Switched to Raltegravir Versus Other Antiretroviral Regimens
Status: Enrolling
Updated: 9/27/2013
Clinical Research Facility
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)
Quality of Life of HIV-infected Patients Switched to Raltegravir Versus Other Antiretroviral Regimens
Status: Enrolling
Updated:  9/27/2013
Clinical Research Facility
mi
from
Miami, FL
Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)
Quality of Life of HIV-infected Patients Switched to Raltegravir Versus Other Antiretroviral Regimens
Status: Enrolling
Updated: 9/27/2013
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)
Quality of Life of HIV-infected Patients Switched to Raltegravir Versus Other Antiretroviral Regimens
Status: Enrolling
Updated:  9/27/2013
Clinical Research Facility
mi
from
Miami, FL
Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)
Quality of Life of HIV-infected Patients Switched to Raltegravir Versus Other Antiretroviral Regimens
Status: Enrolling
Updated: 9/27/2013
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials